CASP3 and neoplasm: Studies have confirmed that the use of ICIs for treating tumours has become increasingly important in tumour immunotherapy (Darvin et al., 2018), and subsequent analysis of the correlation of immunologic checkpoints also revealed that CASP3 plays a significant role in tumours.